This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (37) Citing Articles via Google Scholar Google Scholar Articles by Wadbo, M. Articles by Ström, K. Search for Related Content PubMed PubMed Citation Articles by Wadbo, M. Articles by Ström, K.

Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study

Depts of Respiratory Medicine in ¹ Malmö General University Hospital, Malmö, ² Lund University Hospital, Lund, ³ Karolinska Hospital, Stockholm, ⁴ Sahlgrenska University Hospital, Gothenburg, ⁵ AstraZeneca R&D, Lund, ⁶ Draco Läkemedel AB, Lund, ⁷ Blekinge Hospital, Karlskrona, Sweden

CORRESPONDENCE: K. Ström, Dept of Respiratory Medicine, Norrland University Hospital, S-90185 Umeå , Sweden. Fax: 46 090141369. E-mail: kerstin.strom.@vll.se

Keywords: chronic obstructive pulmonary disease, formoterol, ipratropium, randomised controlled trial, shuttle walking test

Received: December 10, 2001
Accepted June 16, 2002

The aim of this study was to compare the effects of formoterol, ipratropium bromide and a placebo on walking distance, lung function, symptoms and quality of life (QoL) in chronic obstructive pulmonary disease (COPD) patients.

A total of 183 patients (mean age 64 yrs, 86 female) with moderate-to-severe nonreversible COPD participated in this randomised, double-blind, parallel-group study. After a 2-week placebo run-in, patients were randomised to formoterol Turbuhaler® 18 µg b.i.d. (delivered dose), ipratropium bromide 80 µg t.i.d. via a pressurised metered dose inhaler, or placebo for 12 weeks. Inhaled short-acting ß₂-agonists were allowed as relief medication and inhaled glucocorticosteroids were allowed at a constant dose. The primary variable was walking distance in the shuttle walking test (SWT). Baseline mean SWT distance was 325 m, mean forced expiratory volume in one second (FEV₁) was 40% predicted.

Clinically significant improvements in SWT (>30 m) were seen in 41, 38 and 30% of formoterol, ipratropium and placebo patients, respectively (not significant). Mean increases from run-in were 19, 17 and 5 m in the formoterol, ipratropium and placebo groups, respectively. Both active treatments significantly improved FEV₁, forced vital capacity, peak expiratory flow and daytime dyspnoea score compared with placebo. Formoterol reduced relief medication use compared with placebo. Neither active treatment improved QoL.

Formoterol and ipratropium improved airway function and symptoms, without significant improvements in the shuttle walking test.

This article has been cited by other articles:

				S J Singh, P W Jones, R Evans, and M D L Morgan Minimum clinically important improvement for the incremental shuttle walking test Thorax, September 1, 2008; 63(9): 775 - 777. [Abstract] [Full Text] [PDF]

				G. J. Rodrigo, L. J. Nannini, and R. Rodriguez-Roisin Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review Chest, May 1, 2008; 133(5): 1079 - 1087. [Abstract] [Full Text] [PDF]

				S D Aaron, D Fergusson, G B Marks, S Suissa, K L Vandemheen, S Doucette, F Maltais, J F Bourbeau, R S Goldstein, M Balter, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials Thorax, February 1, 2008; 63(2): 122 - 128. [Abstract] [Full Text] [PDF]

				T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline Ann Intern Med, November 6, 2007; 147(9): 639 - 653. [Abstract] [Full Text] [PDF]

				P. Palange, S. A. Ward, K-H. Carlsen, R. Casaburi, C. G. Gallagher, R. Gosselink, D. E. O'Donnell, L. Puente-Maestu, A. M. Schols, S. Singh, et al. Recommendations on the use of exercise testing in clinical practice Eur. Respir. J., January 1, 2007; 29(1): 185 - 209. [Abstract] [Full Text] [PDF]

				M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 343 - 349. [Abstract] [Full Text] [PDF]

				M. Cazzola and R. Dahl Inhaled Combination Therapy With Long-Acting {beta}2-Agonists and Corticosteroids in Stable COPD Chest, July 1, 2004; 126(1): 220 - 237. [Abstract] [Full Text] [PDF]

				E. R. Sutherland and R. M. Cherniack Management of Chronic Obstructive Pulmonary Disease N. Engl. J. Med., June 24, 2004; 350(26): 2689 - 2697. [Full Text] [PDF]

				D. D. Sin, F. A. McAlister, S. F. P. Man, and N. R. Anthonisen Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review JAMA, November 5, 2003; 290(17): 2301 - 2312. [Abstract] [Full Text] [PDF]

				The pharmacoepidemiology of COPD: Recent advances and methodological discussion Eur. Respir. J., September 1, 2003; 22(43_suppl): 1s - 44s. [Full Text] [PDF]